Highlights from the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009

Drugs of the Future

Volumn 34, Issue 11, 2009, Pages 925-934

  Arjono, A ^a   Vasiliou, S ^a   Cole, P ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACT 1; ACU 4429; ALPHA SMOOTH MUSCLE ACTIN; ANECORTAVE; ANTINEOPLASTIC AGENT; BESIFLOXACIN HYDROCHLORIDE; BOL 303242 X; CALCINEURIN INHIBITOR; CALPASTATIN; CEPTOR; COLLAGEN TYPE 1; EDL 155; ENZYME INHIBITOR; GLUCOCORTICOID RECEPTOR; HYDROXYPROPYLCELLULOSE; LX 211; MIMD 3; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; NERVE GROWTH FACTOR; NEURODUR; PENTOSIDINE; PEPTIDOMIMETIC AGENT; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOCLOSPORIN; WOUND HEALING PROMOTING AGENT;

ACCURACY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTROCYTE; AUTOPHAGY; BACTERIAL CONJUNCTIVITIS; BACTERIUM ISOLATE; BLEEDING; BLOOD PRESSURE; BLOOD SAMPLING; CELL DEATH; CHEMICAL STRUCTURE; CONFERENCE PAPER; CONJUNCTIVITIS; CORNEA INJURY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRY EYE; ELECTRON MICROSCOPY; EYE DISEASE; EYE TUMOR; GLAUCOMA; GLAUCOMA SURGERY; GLOMERULUS FILTRATION RATE; GOBLET CELL; HAEMOPHILUS INFLUENZAE; HUMAN; IC 50; INFLAMMATION; INJECTION SITE BLEEDING; INTRAOCULAR PRESSURE; ISOMERIZATION; MAXIMUM PLASMA CONCENTRATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MESENCHYMAL STEM CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHOTORECEPTOR; PHYSICIAN; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINITIS PIGMENTOSA; RETINOBLASTOMA; SCAR FORMATION; SCIENTIST; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; SUBCONJUNCTIVAL HEMORRHAGE; TRABECULECTOMY; TREATMENT INDICATION; UVEITIS; VISION; WOUND HEALING;

EID: 77950600142     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.11.2099354     Document Type: Conference Paper

References (45)

1. Hirami, Y., F. Osakada, F., Takahashi, K., Yamanaka, S., Kurimoto, Y., Takahashi, M. Generation of retinal progenitor cells from human induced pluripotent stem cells. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 3063.
2. Crabb, J.W., Ni, J., Yuan, X., Gu, J., Nagaraj, R.H. Pentosidine and carboxymethyllysine, plasma biomarkers for age-related macular degeneration. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 2330-D1063.
3. Rosenbaum, J.T. LUVENIQ™ (LX211/voclosporin) as corticosteroid-sparing therapy in sight-threatening non-infectious uveitis: Results from three prospective, randomized, multicenter, double-masked, placebo-controlled phase 2/3 clinical trials. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 2021.
4. Wang, X., Patil, R., Yates, C.R., Miller, D.D. A new isoquinoline derivative used to treat retinoblastoma in a rat model. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1687-A267.
5. Boutrid, H., Pina, Y., Jockovich, M.E., Cebulla, C.C., Lampidis, T.J., Murray, T.G. Vascular targeting agent and glycolytic inhibitor combination therapy decreases tumor burden in advanced LHbetaTag murine retinoblastoma. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 2043.
6. Bartels, S.P., Xi, X., Lehmann, G., Feldon, S.E., Phipps, R.P. BOL-303242-X, a selective glucocorticoid receptor agonist (SEGRA), inhibits TGF-β-induced cellular levels of collagen type I, ?-smooth muscle actin, and tissue transglutaminase in human Tenon's capsule fibroblasts (HTF). Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 470-A253.
7. Chen, P., Potts, J., Gourdie, R., Davis, R. A synthetic peptide ACT 1 enhances corneal wound healing. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 6308.
8. Gabison, E.E., Zhang, X., Huet, E. et al. Therapeutic potential of bone marrow mesenchymal stem cells in corneal chemical burns: An in vitro and in vivo study. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 3067.
9. Meerovitch, K., Jain, P., Lama, T. An NGF mimetic, MIM-D3, is a mucin secretogogue. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4261-D864.
10. Li, R., Meerovitch, K., Lama, T., Jain, P., Saragovi, H.U., Cumberlidge, G. An NGF mimetic, MIM-D3 demonstrates therapeutic efficacy in a rat model of scopoloamine-induced dry eye. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 3661-D1009.
11. Koffler, B.H.; LAC-07-01 Study Group. Lacrisert® (hydroxypropyl cellulose ophthalmic insert) significantly improves symptoms of dry eye syndrome and patient quality of life. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4660-D904.
12. Morris, T.W., Haas, W., Brunner, L.S. et al. Clinical efficacy of besifloxacin ophthalmic suspension, integrated microbiological results of 3 trials for topical treatment of bacterial conjunctivitis. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5945.
13. McGee, D.H., Goldenthal, E.I., Gauvin, D., Kubota, R. Nonclinical profile of a novel visual cycle modulator for oral treatment of age-related macular degeneration. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1460-A350.
14. Bavik, C., Murta, K., McGinn, T. et al. Novel therapy for non-exudative AMD. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1217.
15. Kubota, R., Birch, D., David, R. Phase 1, dose-escalating study of the safe-ty, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5009.
16. Rosenbaum, D.M., David, J., Melamud, A., Kesner, L., Rosenbaum, P.S., Barone, F.C., Stracher, A. A novel calpain inhibitor for the treatment of transient retinal ischemia in the rat. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 378-A62.
17. Horsager, A., Liu, J., Boyden, E.S., Arman, A.C., Matteo, B.C., Sampath, A.P., Hauswirth, W.W. Restoring visual function in adult rd1 mice using virally-delivered channelrhodopsin. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 3898.
18. LaRosa, G., Sharma, N., Miller, R. et al. Discovery of non-retinoid pharmacologic chaperones for the treatment of retinitis pigmentosa. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 2302-D1013.
19. Prasanna, G., Krauss, A., Xiang, C. et al. Ocular hypotensive activity and pharmacokinetics of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1466-A356.
20. 4 receptor agonist (PF-04475270) on intraocular pressure in monkeys with unilateral glaucoma. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 812-A144.
21. Podos, S.M., Wang, R.-F., Serle, J.B., Baltatu, O.C. Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1476-A366.
22. Koulen, P., Xin, H., Nguyen, V., Prokai-Tatrai, K., Prokai, L. Unprecedented protection of the retina in a rat model for glaucoma by topical administration of a novel prodrug for 17beta-estradiol. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4327.
23. deLong, M.A., Sturdivant, J.M., Royalty, S.M. et al. Discovery and in vitro SAR of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4058-A220.
24. Yingling, J.D., Arnold, J.J., DeLong, M.A., Lin, C.W., Kopczynski, CC IOP-Lowering efficacy and tolerability of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4063-A225.
25. Wang, R.-F., Serle, J.B., Kopczynski, C. Effect of 0.6% AR-12286 on aqueous humor dynamics in 6 normotensive monkey eyes. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1465-A355.
26. Rhoades, K.L., Patel, Y., Collier, R.J., Romano, C. AL-8309, a serotonin 5-HTIA agonist protects RPE cells from oxidative damage. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 677-D731.
27. Collier, R.J., Martin, E.A., Cully-Adams, C. et al. Serotonin 5-HT1A agonists protect against blue light-induced phototoxicity. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 675-D729.
28. Wang, Y., Martin, E., Hoang, H., Rector, R., Morgan, S., Romano, C., Collier, R. Inhibition of complement deposition by AL-8309a, a 5-HTIa agonist, in the rat photic-induced retinopathy model. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 685-D739.
29. Formica, R., Shen, J., Gong, Y. et al. TM601, a peptide that binds annexin A2, causes regression of choroidal neovascularization (CNV). Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1164-D1126.
30. Schimel, A.M., Abraham, L., Kraus, C., Ercal, N., Apte, R.S. N-Acetylcysteine amide: A potential cure for retinal pigment epithelium oxidative stress and retinal degeneration? Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 669-D723.
31. Boyer, D.S. Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD) - Results of a phase 1 study. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1260.
32. Apte, R.S. Targeting complement factor 5 in neovascular age-related macular degeneration (NV-AMD) - Results of a phase 1 study. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5011.
33. Lott, M.N., Singh, H., Singh, J., Marcus, D.M. Ranibizumab (Lucentis) for polypoidal choroidal vasculopathy. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 6200.
34. Vismara, S., Coscas, F., Calzi, C.I.L., Zourdani, A., Coscas, G. Evaluation by SD-OCT of ranibizumab treatment for vascular polypoidal choroidopathies. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 2360.
35. Williams, G.A., Tao, W. A phase II study of encapsulated CNTF secreting cell implant (NT-501) in patients with visual acuity impairment associated with atrophic macular degeneration. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5003.
36. Lim, J.I., Wieland, M.R., Fung, A., Hung, D.Y., Wong, V. A phase 1 study evaluating the safety and evidence of efficacy of IBI-20089, a triamcinolone intravitreal injection formulated with the Verisome drug delivery technology, in patients with cystoid macular edema. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5395-A346.
37. Webber, A.L., Bilodeau, M.T., Hettrick, L.A. et al. Selection of a KDR kinase inhibitor for local delivery to the eye. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 6243.
38. Heier, J.S. CLEAR-IT 2: Phase 2, randomized, controlled dose-and interval-ranging study of intravitreal VEGF trap eye in patients with neovascular age-related macular degeneration: Predictive factors for visual acuity outcome at one year. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1255.
39. Yzer, S., Missotten, T., Cristiano, J.P.M., Van de Loos, T.L.J.M., Baarsma, G.S., van Hagen, P.M., van den Born, L.I. The effect of somatostatin analogs on cystoid maculopathy in patients with retinitis pigmentosa. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1001-D887.
40. Brinkmann, C.K., Rothenbuehler, S.P., Wolf-Schnurrbusch, U.E.K., Wolf, S. Enhancement of macular pigment by oral lutein supplementation study (EMPOLS): First results. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1708-A288.
41. Zhang, M., Yan, M., Zhang, J., Zhu, W., Luo, D., Yu, D. Safety, tolerability, and biooctivity study of intravitreal KH902 in patients with neovascular age-related macular degeneration. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5004-A605.
42. Nivaggioli, T., Bao, J.X., Farooq, S., Weber, D.A., Naor, J. Pharmacokinetics of a locally administered subconjunctival ocular formulation of sirolimus in rabbits and humans. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 5164.
43. Capone, A., Gonzalez, V.H., Heier, J.S. et al. A phase 1 open-label study of single and repeated doses of intravitreal JSM6427, a small molecule integrin alpha5betal antagonist, in neovascular age-related macular degeneration (AMD). Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 1259.
44. Vogel, R., Slakter, J., Mcleod, K. A phase II, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration: Baseline lesion size, characteristics, and preliminary progression data. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4919.
45. Katz, R.S., Vogel, R., McLeod, K.; Fenretinide Study Group. A phase II multicenter, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration: Preliminary demographic data and reasons for screen failure. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4918-A451.